Pharmaceutical Technology
SEPTEMBER 23, 2022
The CMAs of the company can lower fat throughout the body through mitochondrial uncoupling, a natural process that causes energy regulation. The post Rivus raises $132m to advance clinical development of obesity treatment appeared first on Pharmaceutical Technology.
Outsourcing Pharma
APRIL 29, 2024
OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
APRIL 29, 2024
OSP spoke to Berkeley Research Group healthcare managing director, Wendy Cheng for a discussion around developments in AI regulation for pharmaceuticals, clinical trials, and drug development at a global scale.
Drug Discovery World
SEPTEMBER 6, 2023
It’s great to see companies like Phesi and Krystelis delivering practical solutions and services to help companies meet these new regulations quickly and effectively. The new service harnesses data from Phesi, and uses Krystelis’ writing services to empower sponsors to improve diversity from the trial planning stage onwards.
pharmaphorum
AUGUST 17, 2021
The International Coalition of Medicines Regulatory Authorities (ICMRA) has recommended that a new permanent working group be set up to keep tabs on the use of AI and make sure that regulations can accommodate new developments. The post Global regulators seek permanent working group on AI appeared first on.
Advarra
OCTOBER 4, 2023
When it comes to clinical development, precision, compliance, and quality assurance are paramount. Like any complex and highly regulated industry, the existence of non-conformities and deviations is inevitable. For instance, CAPA in good manufacturing practices (GMP) addresses manufacturing deviations and quality deficiencies.
pharmaphorum
JULY 19, 2022
Face-to-face discussion educates regulators on what matters most to patients, and guides future decision-making. Regulators are increasingly asking drug developers to include the patient voice in submissions, but the best way to go about this is less clear-cut. Personal approach. About the author.
Expert insights. Personalized for you.
242 
Let's personalize your content